S&P 500   4,337.44
DOW   34,006.88
QQQ   359.61
2 Stocks to Benefit from the Aging Population
How is This "Hidden Gem" Thriving in a Turbulent Market? (Ad)
2 Must-Have Silicon Companies That Don't Make Microchips
Small Caps That Have Priced In A Hard Landing For Big Upside
Gold Could Be Heading for Record Highs - But How to Play It? (Ad)
3 Reasons Unity Software Is Ready to Rally 38%
Alcoa, Krispy Kreme fall; Williams-Sonoma, Ford rise, Monday, 9/25/2023
How is This "Hidden Gem" Thriving in a Turbulent Market? (Ad)
Interest rates will stay high 'as long as necessary,' the European Central Bank's leader says
Is Hanes Worth More than the Sum of Its Parts?
S&P 500   4,337.44
DOW   34,006.88
QQQ   359.61
2 Stocks to Benefit from the Aging Population
How is This "Hidden Gem" Thriving in a Turbulent Market? (Ad)
2 Must-Have Silicon Companies That Don't Make Microchips
Small Caps That Have Priced In A Hard Landing For Big Upside
Gold Could Be Heading for Record Highs - But How to Play It? (Ad)
3 Reasons Unity Software Is Ready to Rally 38%
Alcoa, Krispy Kreme fall; Williams-Sonoma, Ford rise, Monday, 9/25/2023
How is This "Hidden Gem" Thriving in a Turbulent Market? (Ad)
Interest rates will stay high 'as long as necessary,' the European Central Bank's leader says
Is Hanes Worth More than the Sum of Its Parts?
S&P 500   4,337.44
DOW   34,006.88
QQQ   359.61
2 Stocks to Benefit from the Aging Population
How is This "Hidden Gem" Thriving in a Turbulent Market? (Ad)
2 Must-Have Silicon Companies That Don't Make Microchips
Small Caps That Have Priced In A Hard Landing For Big Upside
Gold Could Be Heading for Record Highs - But How to Play It? (Ad)
3 Reasons Unity Software Is Ready to Rally 38%
Alcoa, Krispy Kreme fall; Williams-Sonoma, Ford rise, Monday, 9/25/2023
How is This "Hidden Gem" Thriving in a Turbulent Market? (Ad)
Interest rates will stay high 'as long as necessary,' the European Central Bank's leader says
Is Hanes Worth More than the Sum of Its Parts?
S&P 500   4,337.44
DOW   34,006.88
QQQ   359.61
2 Stocks to Benefit from the Aging Population
How is This "Hidden Gem" Thriving in a Turbulent Market? (Ad)
2 Must-Have Silicon Companies That Don't Make Microchips
Small Caps That Have Priced In A Hard Landing For Big Upside
Gold Could Be Heading for Record Highs - But How to Play It? (Ad)
3 Reasons Unity Software Is Ready to Rally 38%
Alcoa, Krispy Kreme fall; Williams-Sonoma, Ford rise, Monday, 9/25/2023
How is This "Hidden Gem" Thriving in a Turbulent Market? (Ad)
Interest rates will stay high 'as long as necessary,' the European Central Bank's leader says
Is Hanes Worth More than the Sum of Its Parts?
NASDAQ:PCVX

Vaxcyte (PCVX) Stock Forecast, Price & News

$50.84
-1.61 (-3.07%)
(As of 09/25/2023 ET)
Compare
Today's Range
$50.78
▼
$52.70
50-Day Range
$46.00
▼
$53.10
52-Week Range
$20.49
▼
$54.97
Volume
1.00 million shs
Average Volume
545,042 shs
Market Capitalization
$4.77 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$65.00
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media

Vaxcyte MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
27.9% Upside
$65.00 Price Target
Short Interest
Bearish
8.04% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.64mentions of Vaxcyte in the last 14 days
Based on 3 Articles This Week
Insider Trading
Selling Shares
$158,460 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($3.07) to ($3.51) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.72 out of 5 stars

Medical Sector

924th out of 962 stocks

Biological Products, Except Diagnostic Industry

156th out of 159 stocks

See Top Rated MarketRank™ Stocks Here

PCVX stock logo

About Vaxcyte (NASDAQ:PCVX) Stock

Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against these emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.

PCVX Price History

PCVX Stock News Headlines

September 24, 2023 | americanbankingnews.com
Vaxcyte (NASDAQ:PCVX) Stock Price Down 2.4%
September 19, 2023 | finance.yahoo.com
Vaxcyte to Present at the 2023 Cantor Fitzgerald Global Healthcare Conference
September 26, 2023 | Edge On The Street (Ad)
Gold Could Be Heading for Record Highs - But How to Play It?
According to FX Empire, the gold forecast is now bullish, with support for a $3,000 target in 2024. The big question is how to play it. Some investors are discovering a unique gold investment alternative that sidesteps the major issues with gold mining stocks or physical gold.
August 22, 2023 | msn.com
Cantor Fitzgerald Reiterates Vaxcyte (PCVX) Overweight Recommendation
August 17, 2023 | msn.com
Strong Financials And Pipeline Position Vaxcyte For Success
August 9, 2023 | msn.com
Needham Reiterates Vaxcyte (PCVX) Buy Recommendation
August 9, 2023 | finanznachrichten.de
Vaxcyte, Inc.: Vaxcyte Reports Second Quarter 2023 Financial Results and Provides Business Update
July 11, 2023 | finance.yahoo.com
Vaxcyte Advances to Second Stage of Ongoing Phase 2 Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease in Infants
September 26, 2023 | Edge On The Street (Ad)
Gold Could Be Heading for Record Highs - But How to Play It?
According to FX Empire, the gold forecast is now bullish, with support for a $3,000 target in 2024. The big question is how to play it. Some investors are discovering a unique gold investment alternative that sidesteps the major issues with gold mining stocks or physical gold.
May 29, 2023 | finance.yahoo.com
Wall Street Analysts Think Vaxcyte, Inc. (PCVX) Could Surge 33.33%: Read This Before Placing a Bet
May 17, 2023 | seekingalpha.com
Vaxcyte: Positive Phase 2 Results Elevate Confidence In VAX-24's Potential
May 15, 2023 | markets.businessinsider.com
BTIG Sticks to Their Buy Rating for Vaxcyte (PCVX)
May 12, 2023 | finance.yahoo.com
Wall Street Analysts Believe Vaxcyte, Inc. (PCVX) Could Rally 26.15%: Here's is How to Trade
May 10, 2023 | morningstar.com
Vaxcyte Inc Ordinary Shares
May 10, 2023 | finance.yahoo.com
Vaxcyte Reports First Quarter 2023 Financial Results and Provides Business Update
May 3, 2023 | finance.yahoo.com
Vaxcyte to Present at the BofA Securities 2023 Health Care Conference
April 21, 2023 | finance.yahoo.com
Vaxcyte Announces Closing of $575 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
April 19, 2023 | finance.yahoo.com
Biotech Stock Roundup: MDGL, PCVX Up on Study Data, MRNA Provides Updates
April 19, 2023 | finanznachrichten.de
Vaxcyte, Inc.: Vaxcyte Announces Pricing of $500 Million Public Offering
April 19, 2023 | msn.com
TD Cowen Initiates Coverage of Vaxcyte (PCVX) with Outperform Recommendation
April 19, 2023 | finance.yahoo.com
Vaxcyte Announces Pricing of $500 Million Public Offering
April 18, 2023 | benzinga.com
Vaxcyte Stock (NASDAQ:PCVX), Dividends
April 17, 2023 | msn.com
New Vaccine Data Sends Vaxcyte Stock Blasting Up
April 17, 2023 | bizjournals.com
Pneumonia vaccine trial data sends Peninsula biotech stock higher
April 17, 2023 | msn.com
Why Vaxcyte Stock Is Sliding After Hours
April 17, 2023 | msn.com
Vaxcyte spikes after mid-stage data for pneumococcal vaccine
April 16, 2023 | finance.yahoo.com
Vaxcyte to Host Webcast and Conference Call to Discuss Results from Phase 2 Study of its 24-Valent Pneumococcal Conjugate Vaccine Candidate in Adults Aged 65 and Older and Full Six-Month Safety Data from Both Adult Phase 2 Studies
See More Headlines
Receive PCVX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Vaxcyte and its competitors with MarketBeat's FREE daily newsletter.

PCVX Company Calendar

Last Earnings
8/08/2023
Today
9/26/2023
Next Earnings (Estimated)
11/06/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:PCVX
CUSIP
N/A
CIK
1649094
Web
www.vaxcyte.com
Phone
650-837-0111
Fax
N/A
Employees
158
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$65.00
High Stock Price Forecast
$70.00
Low Stock Price Forecast
$58.00
Forecasted Upside/Downside
+27.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
6 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($3.36)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-223,490,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-26.20%
Return on Assets
-24.61%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
21.76
Quick Ratio
21.76

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$12.00 per share
Price / Book
4.24

Miscellaneous

Outstanding Shares
93,847,000
Free Float
90,469,000
Market Cap
$4.77 billion
Optionable
Not Optionable
Beta
0.88
7 Stocks to Buy And Hold Forever Cover
7 Stocks to Buy And Hold Forever

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Key Executives

  • Mr. Grant E. Pickering M.B.A. (Age 55)
    Co-Founder, CEO & Director
    Comp: $1.1M
  • Mr. Andrew L. Guggenhime M.B.A. (Age 55)
    Pres & CFO
    Comp: $839.65k
  • Mr. James Wassil M.B.A.Mr. James Wassil M.B.A. (Age 54)
    M.S., Exec. VP & COO
    Comp: $826.3k
  • Mr. Mikhail Eydelman J.D. (Age 42)
    Sr. VP, Gen. Counsel, Chief Compliance Officer & Corp. Sec.
    Comp: $793.22k
  • Mr. Paul W. Sauer M.B.A. (Age 62)
    MBA, Sr. VP of Process Devel. & Manufacturing
    Comp: $608.96k
  • Dr. Ashish Khanna M.B.A. (Age 51)
    Ph.D., Co-Founder
  • Dr. Jeff Fairman Ph.D. (Age 59)
    Co-Founder & VP of Research
  • Ms. Elvia Cowan (Age 50)
    Sr. VP of Fin. & Principal Accounting Officer
  • Ms. Janet Graesser
    VP of Corp. Communications & Investor Relations
  • Karen Alderete
    Exec. Director of HR

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













PCVX Stock - Frequently Asked Questions

Should I buy or sell Vaxcyte stock right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Vaxcyte in the last year. There are currently 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" PCVX shares.
View PCVX analyst ratings or view top-rated stocks.

What is Vaxcyte's stock price forecast for 2023?

6 brokerages have issued 1 year target prices for Vaxcyte's shares. Their PCVX share price forecasts range from $58.00 to $70.00. On average, they anticipate the company's stock price to reach $65.00 in the next year. This suggests a possible upside of 27.9% from the stock's current price.
View analysts price targets for PCVX or view top-rated stocks among Wall Street analysts.

How have PCVX shares performed in 2023?

Vaxcyte's stock was trading at $47.95 at the beginning of the year. Since then, PCVX shares have increased by 6.0% and is now trading at $50.84.
View the best growth stocks for 2023 here.

When is Vaxcyte's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, November 6th 2023.
View our PCVX earnings forecast.

How were Vaxcyte's earnings last quarter?

Vaxcyte, Inc. (NASDAQ:PCVX) posted its quarterly earnings results on Tuesday, August, 8th. The company reported ($0.70) earnings per share for the quarter, beating the consensus estimate of ($0.74) by $0.04.

What ETFs hold Vaxcyte's stock?

ETFs with the largest weight of Vaxcyte (NASDAQ:PCVX) stock in their portfolio include ETFMG Treatments Testing and Advancements ETF (GERM), ALPS Medical Breakthroughs ETF (SBIO), Alger 35 ETF (ATFV), Alger Mid Cap 40 ETF (FRTY), Invesco Dorsey Wright Healthcare Momentum ETF (PTH), SPDR S&P Biotech ETF (XBI), Principal Healthcare Innovators ETF (BTEC) and Virtus LifeSci Biotech Clinical Trials ETF (BBC).

What other stocks do shareholders of Vaxcyte own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Vaxcyte investors own include NVIDIA (NVDA), Twilio (TWLO), Boeing (BA), Overstock.com (OSTK), Pure Storage (PSTG), QUALCOMM (QCOM), Riot Platforms (RIOT), American Tower (AMT), Avid Technology (AVID) and CalAmp (CAMP).

When did Vaxcyte IPO?

(PCVX) raised $210 million in an IPO on Friday, June 12th 2020. The company issued 14,000,000 shares at $14.00-$16.00 per share. BofA Securities, Jefferies and Evercore ISI served as the underwriters for the IPO and Cantor and Needham & Company were co-managers.

What is Vaxcyte's stock symbol?

Vaxcyte trades on the NASDAQ under the ticker symbol "PCVX."

Who are Vaxcyte's major shareholders?

Vaxcyte's stock is owned by a number of retail and institutional investors. Top institutional shareholders include RA Capital Management L.P. (8.41%), BlackRock Inc. (7.53%), Capital Research Global Investors (3.58%), State Street Corp (3.37%), Alliancebernstein L.P. (2.01%) and Braidwell LP (1.84%). Insiders that own company stock include Andrew Guggenhime, Grant Pickering, Group Holdings (Sbs) Advis Tpg, Heath Lukatch, Jane Wright-Mitchell, Jeff Fairman, Jim Wassil, Paul Sauer, Ra Capital Healthcare Fund Lp, Ra Capital Management, LP and Robert Lorne Hopfner.
View institutional ownership trends.

How do I buy shares of Vaxcyte?

Shares of PCVX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Vaxcyte's stock price today?

One share of PCVX stock can currently be purchased for approximately $50.84.

How much money does Vaxcyte make?

Vaxcyte (NASDAQ:PCVX) has a market capitalization of $4.77 billion. The company earns $-223,490,000.00 in net income (profit) each year or ($3.36) on an earnings per share basis.

How many employees does Vaxcyte have?

The company employs 158 workers across the globe.

How can I contact Vaxcyte?

Vaxcyte's mailing address is 353 HATCH DRIVE, FOSTER CITY CA, 94404. The official website for the company is www.vaxcyte.com. The company can be reached via phone at 650-837-0111 or via email at investors@vaxcyte.com.

This page (NASDAQ:PCVX) was last updated on 9/26/2023 by MarketBeat.com Staff

My Account -